SGLT2 Inhibitors and Diabetic Ketoacidosis: Understanding the Euglycemic Risk

Imagine feeling terrible-nauseous, tired, breathing fast-but your blood sugar monitor says you’re fine. For patients taking SGLT2 inhibitors, a popular class of medications for type 2 diabetes that lower blood sugar by removing glucose through urine, this is not just a hypothetical scenario. It is a potentially life-threatening condition known as euglycemic diabetic ketoacidosis (euDKA), a form of diabetic ketoacidosis where blood sugar levels remain normal or only slightly elevated despite dangerous ketone buildup in the blood.

SGLT2 inhibitors like Jardiance (empagliflozin), Farxiga (dapagliflozin), and Invokana (canagliflozin) have revolutionized diabetes care. They offer significant heart and kidney protection, backed by landmark trials like EMPA-REG OUTCOME and CANVAS. However, these benefits come with a unique safety profile. Unlike traditional diabetic ketoacidosis (DKA), which presents with dangerously high blood sugar (usually above 250 mg/dL), euDKA can occur with blood glucose levels below 200 mg/dL. This atypical presentation often leads to delayed diagnosis, increasing the risk of severe complications.

Why Does This Happen? The Mechanism Behind the Risk

To understand why SGLT2 inhibitors trigger this specific type of DKA, we need to look at how they work. These drugs block the sodium-glucose cotransporter-2 in the kidneys, preventing glucose reabsorption and forcing it out into the urine. While this lowers blood sugar, it also signals the body that it is starving for energy.

In response, the body shifts its metabolism. It starts breaking down fat for fuel instead of glucose. This process produces ketones, acidic molecules that are normally harmless in small amounts. But when production outpaces clearance, ketones build up in the blood, causing metabolic acidosis. Normally, high blood sugar would act as a warning sign. With SGLT2 inhibitors, however, the glucose-lowering effect masks this warning. You might feel the symptoms of DKA-abdominal pain, vomiting, rapid breathing-but your meter tells you your sugar is okay. This disconnect is what makes euDKA so dangerous.

The Real Numbers: How Common Is the Risk?

Is this a rare anomaly or a widespread threat? The data shows it’s a serious but manageable risk. According to a 2024 review in the journal *Metabolites*, SGLT2 inhibitor use was associated with an almost 3-fold increase in DKA risk compared to DPP-4 inhibitors (another class of diabetes drugs). Specifically, the incidence was 2.03 events per 1,000 person-years for SGLT2 users versus 0.75 for non-users.

However, context matters. A 2025 network meta-analysis in *Frontiers in Endocrinology* noted that while the relative risk increases, the absolute risk remains low for most patients. The FDA Adverse Event Reporting System analyzed over 1,200 DKA cases linked to SGLT2 inhibitors between 2013 and 2022. Crucially, nearly half (48.7%) of these were classified as euglycemic. The median time to onset was 28 weeks after starting therapy, meaning the first year of treatment requires heightened vigilance.

Who Is Most at Risk? Identifying Precipitating Factors

Not everyone on SGLT2 inhibitors will develop DKA. Certain factors significantly tip the scales. If you fall into one of these categories, you need to be extra cautious:

• Acute Illness: Infections, fever, or flu can stress the body, triggering ketone production. This was the precipitating factor in 32.7% of reported cases.
• Reduced Carbohydrate Intake: Strict low-carb diets, fasting, or skipping meals reduce insulin secretion, promoting fat breakdown.
• Surgery or Procedures: Fasting before surgery is a major trigger. The American Association of Clinical Endocrinologists (AACE) recommends stopping SGLT2 inhibitors at least 3 days before elective surgery.
• Alcohol Consumption: Binge drinking can disrupt metabolism and dehydration, leading to 7.8% of cases.
• Insulinopenia: Patients with type 1 diabetes or type 2 diabetes with very low beta-cell function (C-peptide <1.0 ng/mL) are at higher risk because they lack the insulin reserve to prevent ketone formation.

Recognizing the Symptoms: Don't Ignore Your Body

The challenge with euDKA is that you cannot rely on your glucometer alone. You must listen to your body. The European Association for the Study of Diabetes (EASD) advises checking for these specific symptoms, even if your blood sugar looks normal:

• Nausea or vomiting
• Abdominal pain
• Unusual fatigue or malaise
• Rapid, deep breathing (Kussmaul respirations)
• Fruity-smelling breath

If you experience any of these while taking an SGLT2 inhibitor, do not assume it’s just a stomach bug. Check your ketones immediately.

Action Plan: Prevention and Monitoring Strategies

Managing this risk isn’t about avoiding the medication-it’s about using it smarter. Here is a practical checklist for patients and providers:

1. Get a Ketone Meter: Blood ketone meters are more accurate than urine strips. Keep one at home. If you feel sick, check your ketones. A level above 1.5 mmol/L warrants medical attention.
2. Sick Day Rules: If you are ill, unable to eat, or dehydrated, temporarily stop your SGLT2 inhibitor. Resume it only when you are eating normally and hydrated for at least 24 hours.
3. Surgical Precautions: Inform your surgeon and anesthesiologist that you take an SGLT2 inhibitor. Stop the drug 3 days before any procedure requiring fasting.
4. Avoid Extreme Diets: If you follow a ketogenic or very low-carb diet, discuss the risks with your doctor. You may need closer monitoring or a different medication.
5. Hydration: Drink plenty of water, especially in hot weather or during exercise, to prevent volume depletion.

Regulatory Updates and Future Directions

Health authorities are taking this seriously. The European Medicines Agency (EMA) updated safety recommendations in June 2023, mandating clear warnings about euDKA in all product labels. The FDA has required similar label updates since 2015. Newer guidelines from the American Diabetes Association (2023) explicitly warn against using SGLT2 inhibitors in patients with a history of DKA or those with type 1 diabetes unless under strict specialist supervision.

Looking ahead, pharmaceutical companies are developing SGLT1/2 dual inhibitors, such as licogliflozin, which may offer glucose lowering with a lower risk of ketosis. Additionally, machine learning models are being validated to predict high-risk patients before they even start therapy, allowing for personalized prevention strategies.